The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters

Thrombosis Research

Volumn 130, Issue 5, 2012, Pages 775-779

  Green, Laura ^a   Lawrie, Andrew S ^a   Patel, Rahul ^b   Stephens, Robert C M ^b   MacKie, Ian J ^a   Chitolie, Andrew ^a   Haddad, Fares S ^b   MacHin, Samuel J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

D dimer; Orthopaedic surgery; Prothrombin fragments 1.2; Thrombi antithrombin complexes; Thrombin generation

Indexed keywords

ALPHA 2 MACROGLOBULIN; D DIMER; DABIGATRAN; PROTHROMBIN COMPLEX; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; ECARIN CLOTTING TIME; FEMALE; HEMOCLOT TEST; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN FRAGMENT 1 2; THROMBIN TIME; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; ANTITHROMBINS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBIN;

EID: 84860733455     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.023     Document Type: Article

References (28)

1. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th Edition Chest 133 2008 6 Suppl 381S 453S
2. O.E. Dahl, T. Pedersen, P. Kierulf, A.B. Westvik, P. Lund, and H. Arnesen Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery Thromb Res 70 6 1993 451 458
3. N.E. Sharrock, G. Go, T.P. Sculco, C.S. Ranawat, M.J. Maynard, and P.C. Harpel Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet J Arthroplasty 10 4 1995 523 528
4. N.E. Sharrock, G. Go, P.C. Harpel, C.S. Ranawat, T.P. Sculco, and E.A. Salvati The John Charnley Award. Thrombogenesis during total hip arthroplasty Clin Orthop Relat Res 319 1995 16 27
5. H. Galster, G. Kolb, A. Kohsytorz, C. Seidlmayer, and V. Paal The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups Thromb Res 100 5 2000 381 388
6. L. Green, A.S. Lawrie, S. Patel, F. Hossain, A. Chitolie, and I.J. Mackie The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation Br J Haematol 151 5 2010 469 476
7. M.J. Maynard, T.P. Sculco, and B. Ghelman Progression and regression of deep vein thrombosis after total knee arthroplasty Clin Orthop Relat Res 273 1991 125 130
8. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital NICE clinical guidance 92 2010 1 511 www.nice.org.uk/CG92
9. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, and H. Stahle Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 5 2005 555 563
10. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 3 2007 292 303
11. J. Stangier, H. Stahle, K. Rathgen, and R. Fuhr Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin Pharmacokinet 47 1 2008 47 59
12. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 6 2010 1116 1127
13. R. al Dieri, S. Alban, S. Beguin, and H.C. Hemker Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time J Thromb Haemost 2 8 2004 1395 1401
14. R. al Dieri, S. Alban, S. Beguin, and H.C. Hemker Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight J Thromb Haemost 4 1 2006 83 89
15. A. Gatt, J.J. van Veen, A.M. Woolley, S. Kitchen, P. Cooper, and M. Makris Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro Thromb Haemost 100 2 2008 350 355
16. R. Luddington, and T. Baglin Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition J Thromb Haemost 2 11 2004 1954 1959
17. H.C. Hemker, P. Giesen, D.R. Al, V. Regnault, S.E. De, and R. Wagenvoord Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 1 2003 4 15
18. V. Chantarangkul, M. Clerici, C. Bressi, P.L. Giesen, and A. Tripodi Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability Haematologica 88 5 2003 547 554
19. J.J. van Veen, A. Gatt, P.C. Cooper, S. Kitchen, A.E. Bowyer, and M. Makris Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters Blood Coagul Fibrinolysis 19 3 2008 183 189
20. A. Planes, N. Vochelle, J.Y. Darmon, M. Fagola, M. Bellaud, and Y. Huet Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo Lancet 348 9022 1996 224 228
21. J.H. Scurr, P.D. Coleridge-Smith, and J.H. Hasty Deep venous thrombosis: a continuing problem BMJ 297 6640 1988 28
22. R.J. Wagenvoord, J. Deinum, M. Elg, and H.C. Hemker The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin J Thromb Haemost 8 6 2010 1281 1289
23. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 5 2008 285 295
24. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 11 2007 2178 2185
25. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 9591 2007 949 956
26. J.S. Ginsberg, B.L. Davidson, P.C. Comp, C.W. Francis, R.J. Friedman, and M.H. Huo Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 1 2009 1 9
27. P. Reddy, J.K. Atay, L.G. Selbovitz, J.M. Connors, G. Piazza, and C.C. Block Dabigatran: a review of clinical and pharmacoeconomic evidence Crit Pathw Cardiol 10 3 2011 117 127
28. R.J. Friedman Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials Orthopedics 34 10 2011 795 804